Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Diminishing Returns of Novel Autoantibody Discovery in Encephalitis.

JAMA neurology·2026
Same author

Acute and Long-Term EEG and seizure characteristics in new onset refractory status epilepticus (NORSE).

Epilepsia·2026
Same author

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Highly Selective NaV1.8 Inhibitor JKN2306 in Healthy Chinese Subjects.

Pharmacology research & perspectives·2026
Same author

Tau topography subtypes account for clinical heterogeneity and longitudinal trajectories in early-onset Alzheimer's disease.

Brain communications·2026
Same author

Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio.

JAMA neurology·2026
Same author

Cognitive dispersion profiles and prediction of cognitive change in early-onset dementias: Results from LEADS.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Vanessa M Colón Badillo1, Joseph S Reddy1, Jiangli Jin1

  • 1Mayo Clinic, Jacksonville, FL, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

非洲裔美国人患痴呆症的风险更高. 遗传变异和血转录显示为可访问的阿尔茨海默病 (AD) 生物标志物具有前途,提高了这一群体的诊断准确性.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 遗传学 遗传学 是一个
  • 生物标志物发现发现

背景情况:

  • 与非西班牙裔白人相比,非洲裔美国人 (AA) 患痴呆症的风险增加了一倍,在阿尔茨海默氏症 (AD) 研究中代表性不足.
  • 已经确定了AD的AA特异性风险因素,这表明需要针对性的生物标志物和疗法.
  • 这项研究调查了基因变异和血水平作为AA的潜在AD生物标志物.

研究的目的:

  • 确定与AD风险和血水平相关的遗传变异是否可以作为非洲裔美国人的准确和可访问的AD生物标志物.
  • 为了探索遗传变异,血转录和AA个体和没有AD的AA个体的总tau蛋白水平之间的关联.

主要方法:

  • 在189个AAAD病例和183个AA认知不受损 (CU) 对照中针对10个AD相关位点的向DNA测序.
  • 基因变异与血转录和陶蛋白水平的关联测试,包括当地祖先推断.
  • 接收器操作特征 (ROC) 分析,以评估已识别的e/pQTL和血生物标志物的诊断准确性.

主要成果:

  • 在5,112个测试的变体中,有70个与AD风险和血水平相关;7个变体也与当地祖先相关.
  • 一个包括年龄,性别,33e/pQTL和血水平的模型实现了AD与CU分类的曲线下面积 (AUC) 88.2%.
  • 这种模型在诊断准确度上表现出了30.4%的改进,与只有年龄和性别的基准模型相比.

结论:

  • 血转录水平和表达/蛋白质定量特征位点 (e/pQTLs) 是阿尔茨海默病的有希望的诊断生物标志物.
  • 这些生物标志物可能会提高诊断的可访问性,并降低在非裔美国人中更准确地诊断AD的成本.
  • 对这些生物标志物的进一步研究可能会导致对代表性不足的人群改善AD管理.